Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly gemcitabine chemoradiation for invasive bladder cancer
2004-003906-81Phase 2Active
- Sponsor
- National Cancer Institute
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine in bladder cancer and transitional cell carcinoma (TCC), sponsored by National Cancer Institute. Primary endpoints: Complete response, Toxicity and 4 more. Started Oct 2004; status: active.
02
Drugs
gemcitabine
03
Conditions
bladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2004-003906-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003906-81.